Salem Radio Network News Monday, November 16, 2026

Health

Incyte says EU approves oral treatment for chronic skin disease

Carbonatix Pre-Player Loader

Audio By Carbonatix

Nov 16 (Reuters) – Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin disease.

The drug, Povofortay, chemically known as povorcitinib, was approved for adults with moderate-to-severe hidradenitis suppurativa who have responded inadequately to, or cannot take, anti-tumor necrosis factor therapies.

Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful nodules, abscesses and scarring that can significantly affect patients’ quality of life.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shinjini Ganguli)

Previous
Next
The Media Line News
X CLOSE